Sign up
Pharma Capital

The Hydroponics Company boosts executive team to expand medicinal cannabis strategy

The company is focused on establishing facilities for full-scale vertically integrated processing and production of medicinal cannabis.
Cannabis plants
Ken Charteris, Dr Andrew Beehag and Henry Kinstlinger have been appointed

The Hydroponics Company Ltd (ASX:THC) has made several key executive team additions as it seeks to expand its medicinal cannabis strategy in Australia and Canada.

Ken Charteris, Dr Andrew Beehag and Henry Kinstlinger have the skills and expertise to assist THC’s planned expansion internationally and in particular, in North America and Australia.

READ: The Hydroponics Company at the start of medical cannabis journey, says interim chairman

Chairman Steven Xu said: “THC remains focused on expanding the business, considering further opportunities in Canada as well as expanding the domestic research and manufacture potential.

“We continue to assess a number of short and long-term growth prospects and remain focused on appointing resources to lead this expansion internationally and in particular, in North America and Australia.”

International partnerships established

The company’s Australian medicinal cannabis business has secured operating licences and established valuable international partnerships and supply of product.

This is supported by a solid revenue-generating business in Canada.

THC is focused on establishing facilities for full-scale vertically integrated processing and production of medicinal cannabis.

THC’s new growing facility in Queensland.

This will enable it to supply medicinal cannabis in Australia in the near-term and achieve revenue growth in North America.

Director of Canndeo

Ken Charteris has been appointed as executive director of subsidiary Canndeo, for which he will assume operational control.

He is an internationally experienced chairman and CEO across biotech, pharmaceuticals, and construction industries with a focus on business expansion, acquisition strategy and change management.

Charteris was critical to the acquisition of Canndeo by THC and its establishment as a leader in the cannabis market.

Appointed executive consultant

Beehag has been appointed as an executive consultant working alongside Charteris with both playing major roles in THC’s securing partnership deals with Endoca and BOL Pharma.

They were also pivotal in securing two operating licences from the Office of Drug Control.

In this role, Beehag will ensure continuity in existing deals and regulatory initiatives, as well as advise on viable and monetised directions in new deals.

He brings with him significant experience in the commercialisation of new technologies and in medicinal cannabis.

Joint company secretary

Henry Kinstlinger, a highly experienced company secretary, has been appointed as joint company secretary.

in the past 30 years, he has been actively involved in the financial and corporate management of a number of ASX listed entities and non-governmental organisations.

READ: The Hydroponics Company makes board and management changes, shares jump

They join John Hall who is the senior manager and heads up THC’s cannabis facility in North Queensland and has worked with the team in obtaining the operating licences.

He has consistently focused on the readiness of THC to begin its licensed Australian medicinal cannabis operations both for the current Australian market, as well as government-announced future export potential.

The chairman said: “As one of its earliest investors and now chairman, I have seen the rapid growth of THC to its current status, positioning itself as an international contender in the global cannabis marketplace.”

THC has also appointed an executive search firm to recommend an independent chairman as well as seeking domestic and international candidates that will bring further cannabis industry experience.



Register here to be notified of future THC Company articles
View full THC profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.